This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Aug. 28, 2013



















Not an AzPA member?

Not an AzPA member? Join the only statewide association representing all pharmacy professionals in all pharmacy practice settings.


 



The use of microspheres in parenteral drug delivery
By Dr. Afsaneh Motamed-Khorasani
Drug formulation and delivery is an important process in drug development, where targeted and sustained drug release plays a crucial role in this aspect. Recently, microsphere systems have been used for the sustained release of proteins and chemical drugs. Microspheres provide direct treatment and are capable of delivering the drug to the disease site with lower drug dosing and negligible systemic side effects.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




AREA & ASSOCIATION NEWS


NCPDP releases Medicare Part D Prescription Drug Coordination of Benefits Process white paper
NCPDP via AzPA
The National Council for Prescription Drug Programs recently announced the availability of its "Overview of the Medicare Part D Prescription Drug Coordination of Benefits (COB) Process," which is based on CMS guidance and provides detailed discussion and recommendations related to the coordination of benefits process. The white paper also includes real world accounts of some of the pitfalls encountered in the COB process that have resulted in inaccurate coordination of benefits that can impact Medicare Part D beneficiaries and supplemental payers.

The white paper is intended for Part D Sponsors, State Pharmaceutical Assistance Programs, Prescription Benefit Managers (PBMs), Medicaid agencies, payers offering a supplemental benefit to Medicare beneficiaries, providers that dispense medications to Medicare beneficiaries, pharmacy software vendors, AIDS Drug Assistance Programs (ADAPs), and others that support the coordination of Part D benefits.

The white paper provides a comprehensive explanation of the complex COB process, including:
  • Basic terminology
  • Stakeholders involved in the COB process
  • Overview of Medicare requirements for Part D enrollees
  • Detailed steps to successfully coordinate COB at the point of sale
Download NCPDP's "Overview of the Medicare Part D Prescription Drug Coordination of Benefits (COB) Process."

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Save the date — AzPA Anticoagulation Certificate Program
AzPA



Completely revised, the AzPA Anticoagulation Certificate Program will be presented Oct. 25. Registration will be open in early September.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HIPAA has new rule changes effective Sept. 23. Is your pharmacy ready?
AzPA
There are several changes to the HIPAA Rules that go into effective Sept. 23. Pharmacies need to take action now to avoid repercussions of noncompliance. All pharmacies should review, revise and/or replace their existing HIPAA Compliance Program.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


RxAlly closure announcement
AzPA
Just over 18 months ago, RxAlly brought together an unprecedented alliance of pharmacies united to help patients achieve better health through personalized pharmacist care while reducing costs. The RxAlly board of directors recently decided to close the company effective Aug. 23.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




PHARMACY UPDATES


FDA to regulate compounding pharmacies
MintPress News
After a deadly meningitis outbreak traced to a New England compounding pharmacy killed at least 50 Americans last year, the U.S. government is poised to step in and increase regulation of these niche facilities through the FDA. It could shake up an entire industry struggling to recover from a string of safety and health concerns after increased inspections. Introduced in May, bill S. 959: The Pharmaceutical Quality, Security, and Accountability Act, proposes federal oversight of an industry that allows pharmacists to create custom medications to suit specific patient needs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Newly expanded role for pharmacists in Canada helps manage health of patients
Université de Montréal via News-Medical.Net
The newly expanded role that pharmacists in Canada now have in helping manage the health of patients can benefit both patients and physicians, according to an article in Canadian Medical Association Journal. Pharmacists in Canada have recently been given broader responsibilities, including in some provinces, prescribing privileges, ability to order and interpret laboratory tests and to vaccinate and inject medications. Pharmacists in other countries, such as the United Kingdom, United States and New Zealand, are also increasingly involved in collaborative care arrangements.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE



TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Florida pharmacists win $597 million blowing whistle on scheme (Bloomberg)
New drug approved to treat HIV-1 (HealthDay News)
How the marketplace works: Health insurance (Health Insurance Marketplace)
Backlash against Walgreen new painkiller crackdown (WBUR-FM)
Educate your patients: 5 tips for teaching about insurance (By Jessica Taylor)

Don't be left behind. Click here to see what else you missed.


IN THE NEWS


Use of mood stabilizers for bipolar disorders
By Dr. Abimbola Farinde
The term mood stabilizer first originated with the use of lithium salts when it was discovered they could assist with alleviating mania. Since the introduction of lithium to the United States in 1969, other drugs have been approved and released into the market as mood stabilizers. Along with lithium, other mood stabilizers such as lamotrigine, carbamazepine, valproate and atypical antipsychotics such as olanzapine and aripiprazole have been approved for the prevention of mania, acute mania treatment and depression associated with bipolar disorder.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Are you really in charge?
Pharmacy Practice News
As a pharmacy manager, you have probably agonized over developing the perfect plan to implement a new clinical or operational program. You research the best design. You search the literature and the websites. You speak with countless others who have rolled out similar initiatives. What you likely will determine is that there is no one best plan to accomplish the same clinical or operational goal. After all, why do we have so many different drug distribution programs in hospital pharmacies?
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Doctors face new scrutiny over gifts
The Wall Street Journal
U.S. doctors are bracing for increased public scrutiny of the payments and gifts they receive from pharmaceutical and medical-device companies as a result of the new health law. Companies must record nearly every transaction with doctors — from sales reps bearing pizza to compensation for expert advice on research — to comply with the so-called Sunshine Act provision of the U.S. healthcare overhaul.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


FEATURED ARTICLE
TRENDING ARTICLE
MOST POPULAR ARTICLE
Study: Antipsychotic drugs raise diabetes risk in children
The Wall Street Journal
The use of antipsychotic drugs appears to increase the risk of diabetes in children, not just adults, according to new research. And kids seem to be at an even higher risk, the study found. A number of studies have concluded that adults who take these medications have an elevated risk of developing Type 2 diabetes.

Share on FacebookTwitterShare on LinkedinE-mail article
read more
FDA warns of rare but serious skin reactions with acetaminophen
Pharmacy Practice News
Acetaminophen carries the risk for rare but serious and potentially fatal skin reactions, the FDA warned Aug. 1. The risk is present both in prescription and over-the-counter products containing the pain reliever and fever reducer, whether it is the single active ingredient or is combined with other medications.

Share on FacebookTwitterShare on LinkedinE-mail article
read more
Florida pharmacists win $597 million blowing whistle on scheme
Bloomberg
T. Mark Jones learned about the costs and benefits of healthcare delivery when he treated AIDS patients in Key West, Fla., in the late 1980s. The pharmacy he co-founded provided a humane last step for gay men who didn't want to spend their final weeks confined to a hospital.

Share on FacebookTwitterShare on LinkedinE-mail article
read more


MEDICATION UPDATES


FDA says Mylan's Wellbutrin generic stacks up to branded drug
FiercePharma
Mylan is the first drugmaker to make it through FDA scrutiny of its generic of antidepressant Wellbutrin XL in a regulatory episode that has reignited debate over the quality of generics versus branded drugs. The generics drugmaker said the FDA approved its supplemental Abbreviated New Drug Application after it provided bioequivalence study results in April that had been requested by the FDA for its bupropion hydrochloride tablets.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
Looking for similar articles? Search here, keyword GENERIC DRUGS.


Study: Antipsychotic drugs raise diabetes risk in children
The Wall Street Journal
The use of antipsychotic drugs appears to increase the risk of diabetes in children, not just adults, according to new research. And kids seem to be at an even higher risk, the study found. A number of studies have concluded that adults who take these medications, including risperidone, also called Zyprexa, have an elevated risk of developing Type 2 diabetes.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Amgen to buy Onyx for $10.4 billion
The New York Times
Although Amgen is the world's biggest biotechnology company, the drugmaker has been mostly absent from one of the industry's biggest and fastest-growing markets: cancer drugs. It recently took a big step to fix that, agreeing to buy Onyx Pharmaceuticals for about $10.4 billion in cash to gain access to the company's three anticancer treatments.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 

AzPA Pharmacy Flash
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Danielle Wegert, Content Editor, 469.420.2696   
Contribute news

Disclaimer: The AzPA Pharmacy Flash is a weekly roundup of articles of interest to pharmacists and pharmacy professionals. This email may contain an advertisement of AzPA and/or third party products and services. Opinions expressed in these articles do not necessarily reflect the views of AzPA or its advertising partners. The AzPA Pharmacy Flash is compiled by MultiBriefs, a division of MultiView, Inc. Factual errors are the responsibility of the listed publication.

This edition of the AzPA Pharmacy Flash was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
Aug, 28, 2013
Aug. 21, 2013
Aug. 14, 2013
Aug. 7, 2013



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063